
CLAIMS

1. A compound of ~~f~~Formula I:














Formula I

or a pharmaceutically acceptable salt, hydrate, polymorph, solvate, ~~prodrug,~~ enantiomer, or stereoisomer thereof, wherein:





~~Wherein:~~






R^1 ~~,~~ and R^3 each independently represent~~s D, CH_3, OCH_3, H, OCD_3,~~
























,

,

,

,

,

,

,

,

or

;


R^2 ~~,~~ and R^4 each independently represent~~s~~



,

,

,

,



,

,

,

,

,


,

,

,

,

,























,


,


,


,


,


or


;

each a is independently 2,3 or 7;

each b is independently 3, 5 or 6;

each e is independently 1, 2 or 6;

each c and each d are ~~each~~ independently H, D, -OH, -OD, C_1-C_6-alkyl, -NH_2 or -$COCH_3$; and

each n is independently 1, 2, 3, 4 or 5.

2. A ~~Pharmaceutical~~ pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

3. ~~The~~ Use of the pharmaceutical composition of claim 2~~, which is formulated to treat~~ for treatment of the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.

4. ~~A method of treating mucositis as the underlying etiology, the method~~The use of claim 3 comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition of ~~claim 3.~~ claim 2.

5. The ~~method~~ use of claim 4, wherein the mucositis as the underlying etiology is selected from mucus diseases related to painful inflammation and ulceration of the digestive tract lining and in the mouth.

6. ~~A pharmaceutical composition comprising a molecular conjugate of 2-(2,6-dichlorophenyl)guanidine and R-Lipoic acid.~~ The pharmaceutical composition of claim 2, further comprising a molecular conjugate of 2-(2,6-dichlorophenyl)guanidine and carboxylic acid compounds selected from a group consisting of R-Lipoic acid, acetyl cysteine, caprylic acid, and salsalate.

~~7. A pharmaceutical composition comprising a molecular conjugate of 2-(2,6-dichlorophenyl)guanidine and cyseamine.~~

~~8. A pharmaceutical composition comprising a molecular conjugate of 2-(2,6-dichlorophenyl)guanidine and N-(2,6-dimethylphenyl)acetamide.~~

~~9. A pharmaceutical composition comprising a molecular conjugate of 2-(2,6-dichlorophenyl)guanidine and acetyl cysteine.~~

~~10. A pharmaceutical composition comprising a molecular conjugate of 2-(2,6-dichlorophenyl)guanidine and caprylic acid.~~

~~11. A pharmaceutical composition comprising a molecular conjugate of 2-(2,6-dichlorophenyl)guanidine and salsalate.~~

~~12. A pharmaceutical composition comprising a molecular conjugate of 2-(2,6-dichlorophenyl)guanidine and mesalazine.~~

~~13. A pharmaceutical composition comprising a molecular conjugate of 2-(2,6-dichlorophenyl)guanidine and pentoxifylline.~~

7. The molecular conjugate of claim 6, wherein the carboxylic acid compound is R-Lipoic acid.

8. The molecular conjugate of claim 6, wherein the carboxylic acid compound is acetyl cysteine.

9. The molecular conjugate of claim 6, wherein the carboxylic acid compound is caprylic acid.

10. The molecular conjugate of claim 6, wherein the carboxylic acid compound is salsalate.

11. The pharmaceutical composition of claim 2, further comprising a molecular conjugate of 2-(2,6-dichlorophenyl)guanidine and compounds selected from a group consisting of cysteamine, N-(2,6-dimethylphenyl)acetamide, mesalazine and pentoxifylline.

12. The pharmaceutical composition of claim 2, further comprising a molecular conjugate of 2-(2,6-dichlorophenyl)guanidine and cysteamine.

13. The pharmaceutical composition of claim 2, further comprising a molecular conjugate of 2-(2,6-dichlorophenyl)guanidine and N-(2,6-dimethylphenyl)acetamide.

14. The pharmaceutical composition of claim 2, further comprising a molecular conjugate of 2-(2,6-dichlorophenyl)guanidine and mesalazine.

15. The pharmaceutical composition of claim 2, further comprising a molecular conjugate of 2-(2,6-dichlorophenyl)guanidine and pentoxifylline